Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
NCT06012435 · View on ClinicalTrials.gov ↗
Study Summary
This clinical trial is studying nonsquamous non-small cell lung cancer (NSCLC). Participants in this study must have cancer that has spread through their body or can't be removed with surgery. Participants in this study must have been treated with no more than a platinum-based chemotherapy and an anti-PD-(L)1 drug. Participants with tumors that have certain treatable genomic alterations must have had at least 1 drug for that genomic alteration, in addition to platinum-based chemotherapy. This clinical trial uses an experimental drug called sigvotatug vedotin, which is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial also uses a drug called docetaxel. Docetaxel is an anticancer drug that has been approved to treat non-small cell lung cancer. It is usually given to patients who previously received another anticancer treatment. In this study, one group of participants will get sigvotatug vedotin on Days 1 and 15 during each 28-day-cycle. A second group of participants will get docetaxel on Day 1 during each 21-day cycle. This study is being done to see if sigvotatug vedotin works better than docetaxel to treat participants with NSCLC. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.
Conditions Studied
Interventions
- DRUG sigvotatug vedotin
- DRUG docetaxel
Study Locations (20)
California
- Providence Medical Foundation — Fullerton
- Providence St. Jude Medical Center Virginia K. Crosson Cancer Center and Infusion Center — Fullerton
- Providence St. Jude Medical Center — Fullerton
- Cancer and Blood Specialty Clinic — Los Alamitos
- Cancer Blood and Specialty Clinic — Los Alamitos
- Regulatory Management Only: TRIO-US Central Administration — Los Angeles
- Drug Management Only: UCLA West Medical Pharmacy Attn: Steven L. Wong, Pharma.D. — Los Angeles
- Drug Management Only: UCLA West Medical Pharmacy, Attn: Steven L Wong, Pharm.D. — Los Angeles
- UCSF Medical Center - Mission Bay — San Francisco
- Sansum Clinic — Santa Barbara
- Sansum Clinic — Solvang
Colorado
- Rocky Mountain Cancer Centers LLP — Aurora
- Rocky Mountain Cancer Centers LLP — Boulder
- Rocky Mountain Cancer Centers LLP — Colorado Springs
- Rocky Mountain Cancer Centers LLP — Colorado Springs
- Rocky Mountain Cancer Centers LLP — Denver
- Rocky Mountain Cancer Centers LLP — Denver
- Rocky Mountain Cancer Centers LLP — Lakewood
- Rocky Mountain Cancer Centers LLP — Littleton
Alaska
- Alaska Oncology and Hematology, LLC — Anchorage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 703 participants |
| Start Date | 2024-02-21 |
| Est. Completion | 2028-03-11 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06012435
The ClinicalTrials.gov registry entry for NCT06012435 describes a study currently listed as active not recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 703 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, a wholly owned subsidiary of Pfizer, which has 51 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Carcinoma, Non-Small-Cell Lung appearing as the primary indexed condition, and to 2 interventions — of which sigvotatug vedotin is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06012435 reports 20 study locations spanning 3 distinct geographic areas — top geographies include California, Colorado, Alaska. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06012435 about?
NCT06012435 is a clinical study titled "A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer". This clinical trial is studying nonsquamous non-small cell lung cancer (NSCLC). Participants in this study must have cancer that has spread through their body or can't be removed with surgery. Participants in this study must have been treated with no more than a platinum-based chemotherapy and an an...
What is the current status of trial NCT06012435?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 703 participants. The study started on 2024-02-21. Estimated completion is 2028-03-11.
What conditions does trial NCT06012435 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small-Cell Lung. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06012435?
The interventions under investigation include: sigvotatug vedotin (DRUG), docetaxel (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06012435?
This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 51 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06012435 being conducted?
This trial has 20 study locations across Alaska, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.